...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>ESC Heart Failure >Cardiovascular magnetic resonance imaging and clinical performance of somatostatin receptor positron emission tomography in cardiac sarcoidosis
【24h】

Cardiovascular magnetic resonance imaging and clinical performance of somatostatin receptor positron emission tomography in cardiac sarcoidosis

机译：生长抑素受体正电子发射断层显像在心脏结节病中的心血管磁共振成像和临床表现

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims Cardiac affection constitutes a major limiting condition in systemic sarcoidosis. The primary objective of this study was to investigate the persistence rate of cardiac sarcoid involvement by cardiovascular magnetic resonance (CMR) imaging in patients diagnosed with cardiac sarcoidosis (CS). Moreover, we examined the additional insights into myocardial damage's characteristics gained by somatostatin receptor scintigraphy. Methods and results In a pilot study, we had previously identified cardiac involvement—diagnosed by CMR imaging—to be present in 29 of 188 patients (15.4%) with histologically proven, extra‐CS. Out of these initial 29 CS‐positive patients, 27 patients (49.9?±?11.8?years, 59.3% male) were presently re‐examined and underwent a second CMR study and complementary standard clinical testing. Somatostatin receptor scintigraphy using the ligand 68 Ga‐DOTATOC was additionally performed when clinically indicated (17 patients). Within a median follow‐up period of 2.6?years, none of the initial 29 patients deceased or experienced aborted sudden cardiac death. However, two patients developed third‐degree atrioventricular block that required device therapy. Among the 27 re‐examined CS patients, pathological CMR findings persisted in 14 of 27 patients (51.9%). CS remission was primarily due to a resolution of acute inflammatory processes. 68 Ga‐DOTATOC positron emission tomography/computed tomography (PET/CT) identified one patient with regions of raised tracer uptake that concorded with acute inflammatory changes, as assessed by CMR; this patient received no immunosuppressive medication at the time of PET/CT execution. Conclusions Within follow‐up, CS persisted in barely half the patients, and the patients were not afflicted with cardiac death. Additional 68 Ga‐DOTATOC PET/CT allowed for visualization of acute myocardial inflammation.
机译：目的心脏疾病是全身结节病的主要限制条件。这项研究的主要目的是调查经诊断为心脏结节病（CS）的患者通过心血管磁共振（CMR）成像检查发现的心脏结节病的持续发生率。此外，我们检查了生长抑素受体闪烁显像技术对心肌损伤特征的其他见解。方法和结果在一项前瞻性研究中，我们先前确定了188例经组织学证实的CS外患者中有29例（15.4％）存在心脏受累（通过CMR成像诊断）。在这最初的29名CS阳性患者中，目前有27名患者（49.9±11.8岁），男性59.3％被重新检查，并进行了第二次CMR研究和补充的标准临床测试。当临床上有适应症时（17例患者），还另外进行了使用配体68 Ga-DOTATOC的生长抑素受体闪烁显像。在2.6年的中位随访期内，最初的29名患者均未死亡或经历过人工流产猝死。但是，两名患者出现了三度房室传导阻滞，需要进行器械治疗。在27例重新检查的CS患者中，病理CMR发现在27例患者中的14例中持续存在（51.9％）。 CS缓解主要归因于急性炎症过程的缓解。 68 Ga‐DOTATOC正电子发射断层显像/计算机断层显像（PET / CT）确定了一名患者，其示踪剂摄取量升高的区域与急性炎症改变相一致，根据CMR评估;该患者在执行PET / CT时未接受任何免疫抑制药物治疗。结论在随访中，CS仅持续了一半的患者，并且没有发生心源性死亡。额外的68 Ga-DOTATOC PET / CT可以显示急性心肌炎。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号